Skip to main content
Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLR ISIN · US0167445008 US Manufacturing
Filings indexed 371 across all filing types
Latest filing 2026-04-30 Annual Report
Country US United States of America
Listing US ALLR

About Allarity Therapeutics, Inc.

https://allarity.com/

Allarity Therapeutics is a clinical-stage biopharmaceutical company specializing in precision medicine for oncology. The company utilizes its proprietary Drug Response Predictor (DRP®) companion diagnostic platform to identify patients who are most likely to benefit from its targeted cancer therapies. This approach aims to personalize treatment and improve clinical outcomes. Allarity is advancing a pipeline of in-licensed oncology therapeutics, with its lead candidate being stenoparib, a novel, orally available PARP/tankyrase inhibitor. Stenoparib is primarily being developed for the treatment of advanced ovarian cancer. The company focuses on addressing significant unmet medical needs through its targeted therapeutic development.

Recent filings

Filing Released Lang Actions
ARS - Allarity Therapeutics, Inc. (0001860657) (Filer)
Annual Report
2026-04-30 English
DEF 14A - Allarity Therapeutics, Inc. (0001860657) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
Regulatory Filings
2026-04-28 English
424B3 - Allarity Therapeutics, Inc. (0001860657) (Filer)
Prospectus
2026-04-27 English
S-3/A - Allarity Therapeutics, Inc. (0001860657) (Filer)
Registration Form
2026-04-24 English
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
Regulatory Filings
2026-04-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.